Beställningsvara. Skickas inom 5-8 vardagar. Fri frakt över 249 kr.
Beskrivning
Although more than 10 new antiepileptic drugs have been developed in the past decade, epilepsy remains resistant to drug therapy in about one third of patients, many of whom struggle with the disease their entire lives.
Pharmacoresistance and Epilepsy.- Genes involved in pharmacoresistant epilepsy.- Pathological oscillations in the pharmacoresistant epileptic brain.- Molecular mechanisms of pharmacoresistant epilepsy.- Modifications in the seizures susceptibility by excitotoxic neuronal damage and its possible relationship with the pharmacoresistance.- Intracellular pathways associated with neuronal survival and death in epilepsy.- The role of JNK pathway in the process of excitotoxicity induced by epilepsy and neurodegeneration.- Proteomics-based strategy to identify biomarkers and pharmacological targets in temporal lobe epilepsy.- Abnormalities of GABA system and human pharmacoresistant epilepsy.- Pharmacoresistant epilepsy and immune system.- Contribution of the antiepileptic drug administration regime in the development and/or establishment of pharmacoresistant epilepsy.- Experimental models to study pharmacoresistance in epilepsy.- Resistance to epileptogenesis in the Neotropical rodent Proechimys.- On the development of new antiepileptic drugs for the treatment of pharmacoresistant epilepsy – Different approaches to different hypothesis.- Modulating P-glycoprotein regulation as a therapeutic strategy for pharmacoresistant epilepsy.- Vagus Nerve Stimulation for Intractable Seizures.- The role of neuromodulation in the treatment of refractory epilepsy.- Transcranial magnetic stimulation and refractory partial epilepsy.- Effects of transcranial focal electrical stimulation via concentric ring electrodes on seizure activity.- Physical exercise as a strategy to reduce seizure susceptibility.
